NASDAQ:ARAY - Accuray Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.97 +0.10 (+2.58 %)
(As of 08/20/2018 10:24 AM ET)
Previous Close$3.90
Today's Range$3.90 - $3.97
52-Week Range$3.20 - $6.15
Volume2,500 shs
Average Volume665,301 shs
Market Capitalization$329.71 million
P/E Ratio-10.83
Dividend YieldN/A
Beta1.64
Accuray logoAccuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600

Debt

Debt-to-Equity Ratio3.00
Current Ratio1.62
Quick Ratio0.97

Price-To-Earnings

Trailing P/E Ratio-10.83
Forward P/E Ratio-13.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$383.41 million
Price / Sales0.89
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book7.09

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-29,570,000.00
Net Margins-7.00%
Return on Equity-52.91%
Return on Assets-6.25%

Miscellaneous

Employees944
Outstanding Shares85,640,000
Market Cap$329.71 million

Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) posted its earnings results on Thursday, August, 16th. The medical equipment provider reported ($0.01) EPS for the quarter, topping the Zacks' consensus estimate of ($0.02) by $0.01. The medical equipment provider had revenue of $113.79 million for the quarter, compared to analysts' expectations of $108.45 million. Accuray had a negative return on equity of 52.91% and a negative net margin of 7.00%. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, October, 23rd 2018. View Earnings Estimates for Accuray.

What price target have analysts set for ARAY?

7 Wall Street analysts have issued 12-month price targets for Accuray's stock. Their forecasts range from $3.50 to $10.00. On average, they expect Accuray's stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price. View Analyst Price Targets for Accuray.

What is the consensus analysts' recommendation for Accuray?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.

Who are some of Accuray's key competitors?

Who are Accuray's key executives?

Accuray's management team includes the folowing people:
  • Mr. Joshua H. Levine, Pres, Chief Exec. Officer & Director (Age 60)
  • Mr. Kevin Waters, Sr. VP & CFO (Age 41)
  • Mr. Andrew Kirkpatrick, Sr. VP of Global Operations (Age 55)
  • Mr. Lionel Hadjadjeba, Sr. VP & Chief Commercial Officer (Age 59)
  • Mr. Shigeyuki Hamamatsu, VP of Fin. & Chief Accounting Officer (Age 45)

Has Accuray been receiving favorable news coverage?

News stories about ARAY stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Accuray earned a media and rumor sentiment score of 0.21 on Accern's scale. They also gave media headlines about the medical equipment provider an impact score of 46.23 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Accuray.

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.28%), Partner Fund Management L.P. (5.90%), Renaissance Technologies LLC (5.71%), Russell Investments Group Ltd. (4.98%), Boston Partners (2.82%) and Vident Investment Advisory LLC (2.55%). Company insiders that own Accuray stock include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Institutional Ownership Trends for Accuray.

Which institutional investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Vident Investment Advisory LLC, Boston Partners, Russell Investments Group Ltd., Alambic Investment Management L.P., Legal & General Group Plc and Bank of New York Mellon Corp. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Insider Buying and Selling for Accuray.

Which institutional investors are buying Accuray stock?

ARAY stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Systematic Financial Management LP, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Royce & Associates LP, Mackay Shields LLC, Global X Management Co LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Accuray.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $3.90.

How big of a company is Accuray?

Accuray has a market capitalization of $329.71 million and generates $383.41 million in revenue each year. The medical equipment provider earns $-29,570,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Accuray employs 944 workers across the globe.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]


MarketBeat Community Rating for Accuray (NASDAQ ARAY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel